Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
FDA grants rare paediatric disease designation to RedHill's opaganib
Antengene presents first ATG-207 preclinical data at EULAR 2026
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz